3926
pmol/mouse) was virtually identical with that of the natural sample (ED50=13 pmol/mouse). The
diastereomeric compound 19 was also found to be active in vivo although the potency (ED50=385
pmol/mouse) was about 40 times less than that of 1. These results are somewhat surprising since the
C4 epimer of dysiherbaine model compound was virtually inactive, whereas the model compound with
native stereochemistry at C4 displayed CNS activity.3 Detailed pharmacological properties of 19 along
with the model compounds will be published elsewhere.
In summary, a total synthesis of (−)-dysiherbaine (1) was accomplished from readily available
dianhydrohexose 5. The synthesis described herein should allow for the preparation of a variety of
analogues of this neuroexcitotoxin for further neurobiological studies. Further synthetic studies along
this line are currently underway.
Acknowledgements
This work was financially supported in part by a Grant-in-Aid for Scientific Research from the Ministry
of Education, Science, Sports and Culture, of Japan.
References
1. Sakai, R.; Kamiya, H.; Murata, M.; Shimamoto, K. J. Am. Chem. Soc. 1997, 119, 4112–4116.
2. Matsumori, N.; Kaneno, D.; Murata, M.; Nakamura, H.; Tachibana, K. J. Org. Chem. 1999, 64, 866–876, and references
cited therein.
3. Sasaki, M.; Maruyama, T.; Sakai, R.; Tachibana, K. Tetrahedron Lett. 1999, 40, 3195–3198.
4. A first total synthesis of dysiherbaine (1) has been achieved by the Iwabuchi and Hatakeyama group of Nagasaki University.
They completed the total synthesis by a cross-coupling based strategy very similar to ours and established the absolute
configuration of dysiherbaine as shown in structure 1: Masaki, H.; Maeyama, J.; Kamada, K.; Iwabuchi, Y.; Hatakeyama,
S. In 41th Symposium on the Chemistry of Natural Products; Symposium papers, 1999; pp. 13–18. Very recently, the second
total synthesis has been reported: Snider, B. B.; Hawryluk, N. A. Org. Lett. 2000, 2, 635–638.
5. Palladium(0)-catalyzed cross-coupling reaction of 3 with aryl halides has been successfully used for the preparation of
various amino acids: Jackson, R. F. W.; Wishart, N.; Wood, A.; James, K.; Wythes, M. J. J. Org. Chem. 1992, 57,
3397–3404.
6. Trnka, T.; Cerny, M. Collect.Czech. Chem. Commun. 1971, 36, 2216–2225.
7. Hara, S.; Dojo, H.; Takinami, S.; Suzuki, A. Tetrahedron Lett. 1983, 24, 731–734.
8. Dunn, M. J.; Jackson, R. F. W.; Pietruszka, J.; Wishart, N.; Ellis, D.; Wythes, M. J. Synlett 1993, 499–500.
9. Hydroxy carboxylic acid 16 was easily cyclized to the corresponding δ-lactone under weakly acidic conditions. Therefore,
crude 16 was passed through a short column of neutral SiO2 (10% MeOH–CHCl3 containing 1% Et3N) and immediately
used in the next oxidation reaction.
10. Ley, S. V.; Norman, J.; Griffith, W. P.; Marsden, S. P. Synthesis 1994, 639–666.
11. Following the oxidation of 16 with TPAP/NMO, the usual workup followed by purification by chromatography on silica
gel and esterification with trimethylsilyldiazomethane provided a mixture of spirolactam methyl esters i and ii.
1
12. H NMR data (400 MHz, D2O) for compound 19: δ 4.04 (1H, brdd, J=5.6, 1.7 Hz, 6-H), 3.96 (1H, brs, 9-H), 3.96 (1H,
brd, J=4.3 Hz, 7-H), 3.83 (1H, d, J=13.2 Hz, 10-H), 3.80 (1H, dd, J=11.7, 1.5 Hz, 2-H), 3.49 (1H, m, 8-H), 3.46 (1H, d,
J=13.2 Hz, 10-H), 2.64 (3H, s, NMe), 2.50 (1H, dd, J=15.4, 5.6 Hz, 5-H), 2.36 (1H, dd, J=15.8, 1.5 Hz, 3-H), 2.10 (1H, d,
J=15.4 Hz, 5-H), 2.01 (1H, dd, J=15.8, 11.7 Hz, 3-H).